Sage Investment Counsel LLC Makes New $923,000 Investment in DaVita Inc. (NYSE:DVA)

Sage Investment Counsel LLC acquired a new position in shares of DaVita Inc. (NYSE:DVA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 6,173 shares of the company’s stock, valued at approximately $923,000. DaVita makes up about 1.2% of Sage Investment Counsel LLC’s investment portfolio, making the stock its 18th biggest position.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Blue Trust Inc. increased its position in shares of DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after acquiring an additional 119 shares during the last quarter. Raymond James & Associates increased its position in shares of DaVita by 93.6% during the third quarter. Raymond James & Associates now owns 31,316 shares of the company’s stock worth $5,134,000 after acquiring an additional 15,138 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of DaVita by 1.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock worth $776,000 after acquiring an additional 70 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of DaVita by 8.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 3,482 shares of the company’s stock worth $571,000 after acquiring an additional 269 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in shares of DaVita by 2.1% during the third quarter. DekaBank Deutsche Girozentrale now owns 14,013 shares of the company’s stock worth $2,274,000 after acquiring an additional 292 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the topic of a number of analyst reports. Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. Finally, Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Stock Up 0.7 %

DVA stock opened at $147.83 on Friday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1-year low of $124.70 and a 1-year high of $179.60. The firm has a fifty day moving average price of $160.66 and a two-hundred day moving average price of $158.08. The firm has a market cap of $11.83 billion, a price-to-earnings ratio of 13.76, a PEG ratio of 1.07 and a beta of 0.93.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.